Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
about
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesBeyond ALK-RET, ROS1 and other oncogene fusions in lung cancerThe Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.Over-expression of Orai1 mediates cell proliferation and associates with poor prognosis in human non-small cell lung carcinoma.Anaplastic lymphoma kinase protein expression predicts micrometastases and prognosis for patients with hepatocellular carcinomaProfile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer.Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with CrizotinibAnaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.Drug-diagnostics co-development in oncology.What is the future for cancer clinical trials?
P2860
Q26768158-193D752B-BC34-458F-80C5-CF7711DA9E8BQ26851421-A962EE59-35C0-4196-896D-E8AA6822F234Q35532823-9F9F9FF3-4A60-439D-B0EA-AE6F08CC4EC2Q35854064-96ECF0D7-B670-4E2D-979C-964586C76B4AQ36502649-130DC822-6C52-4EB0-A7B9-B92992C760C4Q37566828-D7B409EC-FB49-4F59-9096-2919C1E896DEQ38567805-CC54FC33-C0BD-48FD-B936-DBE27371E12AQ38669285-AB2A6FA5-EC00-498F-A9F5-A6516B2B1A1DQ38829675-7F5E1C10-2D19-48C6-A5B7-D6656EC17A0DQ41883789-4FA3613C-A02F-4FFE-B80E-FAD58B92C2DCQ48639219-43DC154F-D60D-4F93-90E6-945309037455
P2860
Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Will the Requirement by the US ...... all Cell Lung Cancer Globally?
@ast
Will the Requirement by the US ...... all Cell Lung Cancer Globally?
@en
Will the Requirement by the US ...... all Cell Lung Cancer Globally?
@nl
type
label
Will the Requirement by the US ...... all Cell Lung Cancer Globally?
@ast
Will the Requirement by the US ...... all Cell Lung Cancer Globally?
@en
Will the Requirement by the US ...... all Cell Lung Cancer Globally?
@nl
prefLabel
Will the Requirement by the US ...... all Cell Lung Cancer Globally?
@ast
Will the Requirement by the US ...... all Cell Lung Cancer Globally?
@en
Will the Requirement by the US ...... all Cell Lung Cancer Globally?
@nl
P2093
P2860
P356
P1476
Will the Requirement by the US ...... all Cell Lung Cancer Globally?
@en
P2093
Akihito Kubo
Myung-Ju Ahn
Ross A. Soo
Tomoya Kawaguchi
P2860
P356
10.3389/FONC.2014.00058
P407
P577
2014-01-01T00:00:00Z